Request Trial
Gorodenkoff / Shutterstock.com
6 August 2025NewsPharmaCamille Terfve and Sean Jauss

Chemical reaction: Why AI drug discovery demands a new IP plan

With AI accelerating drug development, pharma companies must rethink how they protect models, data, and innovation, say Camille Terfve and Sean Jauss of Mewburn Ellis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
12 August 2026   Reflecting on decades of patent searching experience, senior scientist on the CAS IP Services team, David Saari, offers insights into the importance of a multidisciplinary approach in today's competitive IP landscape.
Pharma
Lilly mounts defence as generics circle Mounjaro and Zepbound
11 August 2026   A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.
Pharma
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
10 August 2026   Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.


Editor's picks

Where Big Pharma is betting big in the M&A boom
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

Editor's picks

Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Regulation & Industry
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026

More features

Invisalign maker secures first China win against clear aligner rival
Holland & Hart adds high-stakes patent litigation team from Ashurst Perkins Coie
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
Exclusive: ‘In the end, I did it my own way’ and became a UPC judge
Lilly mounts defence as generics circle Mounjaro and Zepbound
Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany
Kirkland clears conflicts hurdle in trade secrets spat
Former senior attorney-advisor to ITC commissioners joins Mintz